AMPK/mTOR
AMP-activated protein kinase (AMPK) and the Mechanistic target of rapamycin (mTOR) (Mtor) constitute a functionally opposing signaling axis at the center of cellular energy sensing.
AMP-activated protein kinase (AMPK) and the Mechanistic target of rapamycin (mTOR) (Mtor) constitute a functionally opposing signaling axis at the center of cellular energy sensing. AMPK is a heterotrimeric serine/threonine kinase activated when the AMP:ATP ratio rises, through the upstream kinases LKB1 and CaMKK2; once active, it promotes catabolic processes including autophagy, fatty acid oxidation, and mitochondrial biogenesis. Mtor, acting mainly through mTORC1, is the anabolic counterpart, stimulating protein and lipid biosynthesis and cell growth while suppressing autophagy. The two are mutually antagonistic: AMPK inhibits mTORC1 both directly and through TSC2, shifting the cell from growth toward energy conservation and quality-control recycling. That reciprocity makes the axis a master regulator of autophagy flux, mitochondrial integrity, and cell survival, and a high-value drug target in metabolic disease, neurodegeneration, and cancer.
Around this core sits a wider regulatory network. AMPK and Sirtuin 1 (SIRT1) (Sirt1) activate each other reciprocally rather than in one direction, and their joint output runs downstream through Forkhead box O3 (FOXO3) (FOXO3a) to superoxide dismutase and catalase, coupling energy status to the antioxidant response; oxidative stress feeds back on AMPK in turn. On the anabolic side, Mtor integrates nutrient and growth-factor input via Protein kinase B (PKB) and drives lipogenesis through SREBP-1c. Dysregulation of either kinase is implicated in type 2 diabetes, Alzheimer's disease, osteoporosis, epilepsy, metabolic dysfunction-associated steatohepatitis (MASH), glycogen storage disorders, and multiple cancers, which is why the balance between AMPK activity and Mtor suppression, rather than either kinase alone, is the therapeutic variable.
Where the papers sit
10 papers from the last 6 months study AMPK/mTOR directly · updated from PubMed 4 Oct 2026
Study type 0 clinical trials · 8 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Autophagy and Metabolic Signaling
AMPK/mTOR signaling is being used to connect autophagy with tissue injury, cancer differentiation and ferroptosis. Betulinic acid and Yishen Tongluo Formula are explored as autophagy-promoting interventions, whereas mTOR inhibition supports ATRA-induced differentiation. In epilepsy, suppressing aerobic glycolysis activates AMPK-FoxO3a and reduces ferroptosis. Mechanotherapeutic biomaterials add a delivery-focused cancer application, leaving the overall field broad but pathway-centered.
5 papers · 50%
-
Metabolic Tissue Protection
AMPK-linked metabolic dysfunction is being studied as a target for tissue protection across gut, brain and liver. Empagliflozin restores the colonic mucous barrier through AMPK/SOX4 in glycogen storage disease type Ib, while dexmedetomidine engages AMPK/SIRT1 in Alzheimer’s disease. Endothelial glycogen synthase kinase 3β links lipotoxic endotheliopathy to liver inflammation in MASH. The pathway is recurrent, but the disease contexts and interventions remain distinct rather than converging on one treatment.
3 papers · 30%
-
CHK1 AMPK Cancer Vulnerability
Cancer-cell killing is being framed as a dual CHK1–AMPK vulnerability rather than CHK1 inhibition alone. Prexasertib cytotoxicity is attributed to simultaneous inhibition of both kinases. The work positions this interaction as a mechanism of lethal stress in tumor cells, with EXO1 and CAMKK2 among the associated regulators. Whether dual inhibition can produce a selective therapeutic window remains open.
2 papers · 20%
AMPK inhibition becomes a direct contributor to kinase-inhibitor cytotoxicity rather than a therapeutic mechanism for restoring cellular homeostasis
Prexasertib-treated cancer cells are the subject of PMID 42061410, which found that prexasertib binds AMPK, ultimately inhibits its activity, and kills cells through combined CHK1 and AMPK inhibition. The other intervention studies use AMPK signaling chiefly as a protective or corrective pathway—activating it to support autophagy, energy balance, barrier repair, or stress resistance—whereas this study assigns AMPK a distinct role as a direct pharmacologic vulnerability whose inhibition enhances CHK1-inhibitor sensitivity, potentially through Exo1 hyperactivation. This expands the frame from AMPK/mTOR signaling as a pathway to stimulate therapeutically to AMPK as a drug target whose suppression can be required for cancer-cell death.
Papers
The 10 papers from the last 6 months that study AMPK/mTOR directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Autophagy and Metabolic Signaling (5)
- Yishen Tongluo Formula Regulates Apoptosis and Autophagy in Testicular Spermatogenic Cells of Oligoasthenozoospermic Rats via the AMPK/mTOR Pathway. Journal of ethnopharmacology · 22 Jul 2026 PMID 42486454
- Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours. Biomedical microdevices · 23 Jun 2026 PMID 42334617
- Betulinic acid alleviates the inflammatory injury of osteoblasts in osteoporosis by augmenting autophagy via the AMPK-mTOR signaling pathway. International journal of molecular medicine · 15 May 2026 PMID 42138188
- Inhibition of aerobic glycolysis suppresses ferroptosis via activation of the AMPK-FoxO3a pathway in epileptic rats. Molecular biology reports · 13 May 2026 PMID 42126735
- mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state. Journal of translational medicine · 12 May 2026 PMID 42116148
Metabolic Tissue Protection (3)
- The protective effects of dexmedetomidine via AMPK/SIRT1 pathway activation in a rat model of alzheimer's disease: evidence from preliminary findings. Molecular biology reports · 10 Jun 2026 PMID 42268445
- Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 May 2026 PMID 42133539
- Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH. JCI insight · 5 May 2026 PMID 42084928
CHK1 AMPK Cancer Vulnerability (2)
- Dangerous liaisons: Promiscuous inhibition of CHK1 and AMPK is a lethal affair for cancer cells. Cell chemical biology · 18 Jun 2026 PMID 42314651
- The cytotoxic effect of prexasertib is a consequence of dual inhibition on both CHK1 and AMPK. Cell chemical biology · 30 Apr 2026 PMID 42061410
By study type
Preclinical: animal, cell and lab studies (8)
- Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours. Biomedical microdevices · 23 Jun 2026 PMID 42334617
- Dangerous liaisons: Promiscuous inhibition of CHK1 and AMPK is a lethal affair for cancer cells. Cell chemical biology · 18 Jun 2026 PMID 42314651
- The protective effects of dexmedetomidine via AMPK/SIRT1 pathway activation in a rat model of alzheimer's disease: evidence from preliminary findings. Molecular biology reports · 10 Jun 2026 PMID 42268445
- Betulinic acid alleviates the inflammatory injury of osteoblasts in osteoporosis by augmenting autophagy via the AMPK-mTOR signaling pathway. International journal of molecular medicine · 15 May 2026 PMID 42138188
- Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 14 May 2026 PMID 42133539
- Inhibition of aerobic glycolysis suppresses ferroptosis via activation of the AMPK-FoxO3a pathway in epileptic rats. Molecular biology reports · 13 May 2026 PMID 42126735
- mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state. Journal of translational medicine · 12 May 2026 PMID 42116148
- The cytotoxic effect of prexasertib is a consequence of dual inhibition on both CHK1 and AMPK. Cell chemical biology · 30 Apr 2026 PMID 42061410
Unclassified: not yet indexed with MeSH (2)
- Yishen Tongluo Formula Regulates Apoptosis and Autophagy in Testicular Spermatogenic Cells of Oligoasthenozoospermic Rats via the AMPK/mTOR Pathway. Journal of ethnopharmacology · 22 Jul 2026 PMID 42486454
- Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH. JCI insight · 5 May 2026 PMID 42084928
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.